905 West Pender Street
Suite 503
Vancouver, BC V6C 1L6
Canada
https://www.biovaxys.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. James Christopher Passin | Co-Founder, CEO & Director | 7.68k | N/A | 1972 |
Mr. Kenneth E. Kovan | Co-Founder, Pres & COO | 15.48k | N/A | 1963 |
Mr. Lachlan McLeod CPA | CFO & Corp. Sec. | 11.52k | N/A | 1988 |
Dr. David Berd | Co-Founder & Chief Medical Officer | N/A | N/A | 1943 |
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
BioVaxys Technology Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.